The Onchocerciasis Research Network Meeting took place during the 11th DNDi Partners’ Meeting.
Opening
Date: Wednesday, 3 October 2018
Time: 08:00-8:15
Venue: Room Royal, Speke Resort and Conference Centre
Welcome & meeting objectives | Sabine Specht, Head of Filariasis Clinical Programme, DNDi, Switzerland Belén Pedrique, Medical Manager, Filariasis Programme, DNDi, Switzerland |
Sessions
Onchocerciasis in Africa
Time: 08:15-10:45
Progress of onchocerciasis programs in Africa and the challenges to reach elimination |
Country-specific situation of clinical trials and research – Ghana |
Cameroon: Country progress towards elimination and research update |
DRC: Country progress towards elimination and research update |
Uganda: Country progress towards elimination |
Uganda: New vector control methods under research |
Uganda: Onchocerciasis associated epilepsy and nodding syndrome research |
Platforms and Research Centres: Sharing experiences
Time: 11:00-14:30
KCCR Kumasi, Ghana and TAKeOFF platform (Tackling the Obstacle to Fight Filariasis and Podoconiosis) |
UHAS |
CRMT Rethy |
REFODTE, Buea Cameroon |
CRFilMT, Yaounde Cameroon and CANTAM |
NSETHIO project |
HAT platform experience |
Current research landscape in onchocerciasis – Part 1
Time: 14:30-15:30
Clinical research in onchocerciasis – DOLF |
Clinical research in onchocerciasis – Bonn University |
Clinical research in onchocerciasis – TNT project and other studies |
Current research landscape in onchocerciasis – Part 2
Date: Thursday, 4 October 2018
Time: 8:00-9:00
Alternative Strategies for the Acceleration of Elimination of Onchocerciasis in Cameroon |
Moxidectin studies: community study comparing moxidectin and ivermectin in Ituri, DRC |
Moxidectin pediatric study in Ghana |
Onchocerciasis: What are the patients’ needs?
Time: 9:00-9:30
Unmet Medical Need of onchocerciasis patients and DNDi landscape – Target Product Profile for onchocerciasis case management |
Registration & access of new drugs in Africa
Time: 9:45-10:15
Moxidectin experience for FDA registration and options for registration in Africa |
Access strategies for new treatments |